ATTAIN-1
The Phase 3 trials that won approval, and the outcome studies that came afterward on cardiovascular, kidney and sleep-apnea endpoints.
What is ATTAIN-1?
Orforglipron's phase 3 in weight management, run in adults who had obesity but not diabetes: 72 weeks, N=3,127, across ten countries (NCT05869903).
On the efficacy estimand the 17.2 mg arm lost 12.4% of body weight where placebo lost 0.9%.
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where ATTAIN-1 comes up on this site
On GLP Watchdog, ATTAIN-1 comes up in 4 tools.
Tools that use it
Connected terms
Other terms under Major trials
Where the evidence lives
- Foundayo drug overview
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers